Axsome Therapeutics announced it will report Q2 2026 financial results on August 10, 2026, followed by a management conference call at 8:00 a.m. ET. The company is advancing its CNS disorder treatment portfolio with FDA-approved products including SUNOSI, AUVELITY, and SYMBRAVO, while progressing multiple clinical trials including Phase 3 FOCUS-2 and FOCUS-3 trials for solriamfetol in pediatric and adolescent ADHD patients.

Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.

Axsome Therapeutics has experienced significant growth with its CNS disorder treatments, including recently approved drugs Auvelity for Alzheimer's agitation and Symbravo for migraines. While the stock has climbed 220% over three years and has strong revenue growth, the article cautions that reaching millionaire status from a single stock investment is unrealistic, recommending instead a diversified portfolio approach.

Axsome Therapeutics announced the initiation of the FOCUS-3 Phase 3 trial evaluating solriamfetol for treating ADHD in adolescents aged 12-17. The randomized, double-blind, placebo-controlled trial will enroll approximately 468 patients across multiple centers over 6 weeks, with the primary endpoint measuring changes in ADHD Rating Scale scores.

Hypercharge Networks Corp. announced the grant of 2,630,000 stock options at an exercise price of $0.08 and 1,115,464 deferred share units to directors, officers, employees, and consultants. The company also announced it was named co-winner of the Canada Growth Cup and grew its total charging ports by over 45% through the acquisition of Eddie from AXSO, adding over 2,700 ports under management.

The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.

Axsome Therapeutics announced presentations of new clinical data for SYMBRAVO® (meloxicam and rizatriptan) at the American Headache Society's 68th Annual Scientific Meeting in Orlando, FL (June 4-7, 2026). Four poster presentations will showcase efficacy, safety, and comparative effectiveness data from Phase 3 trials MOMENTUM and MOVEMENT, as well as network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment.

Axsome Therapeutics announced its support for Migraine and Headache Awareness Month in June 2026, partnering with the Headache Alliance to promote educational initiatives. The company is supporting the first annual 'Headache in the City' campaign on June 15 in New York City and will illuminate its headquarters at One World Trade Center in purple to raise awareness. Axsome also shared resources from leading migraine advocacy organizations to help patients access care and treatment information.

Axsome Therapeutics announced its participation in five major investor conferences scheduled for June 2026, including William Blair Growth Stock Conference, Jefferies Global Healthcare Conference, Goldman Sachs Global Healthcare Conference, Oppenheimer CNS and Neuro-Muscular Summit, and UBS Virtual CNS Day. The company will host fireside chats at each event, with webcasts available on its investor relations website.

The healthcare industry is shifting toward data-driven, precision medicine models powered by AI and genomic data. Three companies are positioned to lead this transformation: Tempus AI is building a healthcare data platform with network effects; Recursion Pharmaceuticals is accelerating drug discovery through automation and machine learning; and Axsome Therapeutics is gaining traction with fast-acting CNS treatments, particularly its antidepressant Auvelity.

Axsome Therapeutics announced its participation in two major investor conferences in May 2026: BofA Securities Health Care Conference on May 12 and RBC Capital Markets Global Healthcare Conference on May 19. The company will host fireside chats at both events, with webcasts available on its investor relations website.

Hypercharge Networks Corp. has acquired Eddie, an EV charging network operator, from AXSO, adding over 2,700 charging ports (45% growth) and strengthening its presence in Quebec, Canada's largest EV market. The transaction is non-dilutive and accretive on day one, expected to increase recurring revenue and support Hypercharge's path to profitability.